{"filing":{"accession_number":"0001087294-26-000058","cik":"0001087294","ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"cpix-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000058/cpix-20260804.htm"},"events":[{"id":23746,"run_id":21477,"accession_number":"0001087294-26-000058","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cumberland Pharmaceuticals issued a press release on August 4, 2026, disclosing financial results for the three and six months ended June 30, 2026, including net revenues, operating losses, balance sheet data, and cash flow statements. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is attached as Exhibit 99.1. While the filing also discusses a material strategic transaction with Apotex and a special dividend, the primary disclosure mechanism and Item classification is the earnings release itself.","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24064,"accession_number":"0001087294-26-000058","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cumberland Pharmaceuticals issued a press release on August 4, 2026, disclosing financial results for the three and six months ended June 30, 2026, including net revenues, operating losses, balance sheet data, and cash flow statements. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is attached as Exhibit 99.1. While the filing also discusses a material strategic transaction with Apotex and a special dividend, the primary disclosure mechanism and Item classification is the earnings release itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:34:17.458717+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24064,"accession_number":"0001087294-26-000058","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cumberland Pharmaceuticals issued a press release on August 4, 2026, disclosing financial results for the three and six months ended June 30, 2026, including net revenues, operating losses, balance sheet data, and cash flow statements. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is attached as Exhibit 99.1. While the filing also discusses a material strategic transaction with Apotex and a special dividend, the primary disclosure mechanism and Item classification is the earnings release itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:34:17.458717+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-08-04"}]}